• Microba and Sonic Healthcare signed a commercial agreement to sell Microba's advanced infectious disease testing technology MetaPanel™ in Australia
• This new metagenome diagnostic test contributes to improving the standard treatment of gastrointestinal infectious disease pathology by identification of a comprehensive panel of pathogenic microorganisms and genes.
• It is the first agreement between the two companies since Sonic Healthcare (ASX: SHL) acquired 19.99% of Microva's shares, and the two companies are the world's leading microbiome testing technology of Microba as the main of Sonic Healthcare. It will be the first step to put it into the market.

This announcement of the MetaPanel™ sales contract is the first commercial contract signed since Sonic Healthcare's strategic investment of $17.8 million in microba on November 29, 2022. In this investment, Sonic and Microva agreed on the initial terms of a strategic partnership to sell Microba's microbiome testing technology to major markets of Sonic Healthcare. With the conclusion of this sales agreement, the first phase of the commercial sales arrangement will be completed, and the MetaPanel™ test will be sold throughout Australia through Sonic Healthcare's Australian Pathology Network.

Dr. Luke Reed, CEO of Microba, said, "Through Sonic Healthcare's professional national laboratory network, we can provide Microba's testing products to clinicians and patients across Australia. I'm happy to be. MetaPanel™'s technology has been developed for many years and is ahead of the world in pathology with comprehensive metagenome testing for gastrointestinal infections. Sonic Healthcare provides high-quality pathology testing services on the front line and will lead commercialization efforts to provide MetaPanel™ testing throughout Australia. Sonic Australia will be the first region to sell microba technology, and we are planning to sell our inspection technology and products through partnerships to further markets around the world."